Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2014
|
| _version_ | 1797057755795685376 |
|---|---|
| author | Reilly, J Mcmullin, M Beer, P Butt, N Conneally, E Duncombe, A Green, A Mikhaeel, G Gilleece, M Knapper, S Mead, A Mesa, R Sekhar, M Harrison, C |
| author_facet | Reilly, J Mcmullin, M Beer, P Butt, N Conneally, E Duncombe, A Green, A Mikhaeel, G Gilleece, M Knapper, S Mead, A Mesa, R Sekhar, M Harrison, C |
| author_sort | Reilly, J |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T19:40:57Z |
| format | Journal article |
| id | oxford-uuid:20a5de2e-5a88-4a07-a8ab-3805ed0342f2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:40:57Z |
| publishDate | 2014 |
| publisher | Blackwell Publishing Ltd |
| record_format | dspace |
| spelling | oxford-uuid:20a5de2e-5a88-4a07-a8ab-3805ed0342f22022-03-26T11:28:45ZUse of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:20a5de2e-5a88-4a07-a8ab-3805ed0342f2EnglishSymplectic Elements at OxfordBlackwell Publishing Ltd2014Reilly, JMcmullin, MBeer, PButt, NConneally, EDuncombe, AGreen, AMikhaeel, GGilleece, MKnapper, SMead, AMesa, RSekhar, MHarrison, C |
| spellingShingle | Reilly, J Mcmullin, M Beer, P Butt, N Conneally, E Duncombe, A Green, A Mikhaeel, G Gilleece, M Knapper, S Mead, A Mesa, R Sekhar, M Harrison, C Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012 |
| title | Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012 |
| title_full | Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012 |
| title_fullStr | Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012 |
| title_full_unstemmed | Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012 |
| title_short | Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012 |
| title_sort | use of jak inhibitors in the management of myelofibrosis a revision of the british committee for standards in haematology guidelines for investigation and management of myelofibrosis 2012 |
| work_keys_str_mv | AT reillyj useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT mcmullinm useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT beerp useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT buttn useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT conneallye useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT duncombea useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT greena useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT mikhaeelg useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT gilleecem useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT knappers useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT meada useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT mesar useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT sekharm useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 AT harrisonc useofjakinhibitorsinthemanagementofmyelofibrosisarevisionofthebritishcommitteeforstandardsinhaematologyguidelinesforinvestigationandmanagementofmyelofibrosis2012 |